Belite Bio, Inc

NASDAQ:BLTE

69.9 (USD) • At close November 1, 2024
Bedrijfsnaam Belite Bio, Inc
Symbool BLTE
Munteenheid USD
Prijs 69.9
Beurswaarde 1,564,135,244
Dividendpercentage 0%
52-weken bereik 31.005 - 70.365
Industrie Biotechnology
Sector Healthcare
CEO Dr. Yu-Hsin Lin M.B.A., Ph.D.
Website https://belitebio.com

An error occurred while fetching data.

Over Belite Bio, Inc

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the

Vergelijkbare Aandelen

Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc.

GLUE

8.9 USD

Esperion Therapeutics, Inc. logo

Esperion Therapeutics, Inc.

ESPR

2.03 USD

Regencell Bioscience Holdings Limited logo

Regencell Bioscience Holdings Limited

RGC

8.09 USD

Kodiak Sciences Inc. logo

Kodiak Sciences Inc.

KOD

3.84 USD

Tyra Biosciences, Inc. logo

Tyra Biosciences, Inc.

TYRA

16.39 USD

Inotiv, Inc. logo

Inotiv, Inc.

NOTV

1.78 USD

Arcellx, Inc. logo

Arcellx, Inc.

ACLX

86.17 USD

MeiraGTx Holdings plc logo

MeiraGTx Holdings plc

MGTX

5.81 USD

Viridian Therapeutics, Inc. logo

Viridian Therapeutics, Inc.

VRDN

22.28 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)